[go: up one dir, main page]

WO2018077958A1 - Composition de soins personnels comprenant des curcuminoïdes - Google Patents

Composition de soins personnels comprenant des curcuminoïdes Download PDF

Info

Publication number
WO2018077958A1
WO2018077958A1 PCT/EP2017/077327 EP2017077327W WO2018077958A1 WO 2018077958 A1 WO2018077958 A1 WO 2018077958A1 EP 2017077327 W EP2017077327 W EP 2017077327W WO 2018077958 A1 WO2018077958 A1 WO 2018077958A1
Authority
WO
WIPO (PCT)
Prior art keywords
formula
composition
compound
curcumin
skin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2017/077327
Other languages
English (en)
Inventor
Clive Roderick Harding
Bijan Harichian
Helen Mary MUIR-HOWIE
Jose Guillermo Rosa
Luxian ZHOU
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Unilever NV
Conopco Inc
Original Assignee
Unilever NV
Conopco Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Unilever NV, Conopco Inc filed Critical Unilever NV
Publication of WO2018077958A1 publication Critical patent/WO2018077958A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/35—Ketones, e.g. benzophenone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/906—Zingiberaceae (Ginger family)
    • A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/004—Aftersun preparations
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
    • C07C45/65—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by splitting-off hydrogen atoms or functional groups; by hydrogenolysis of functional groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
    • C07C45/67—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton
    • C07C45/68—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
    • C07C45/67—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton
    • C07C45/68—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms
    • C07C45/72—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms by reaction of compounds containing >C = O groups with the same or other compounds containing >C = O groups
    • C07C45/74—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms by reaction of compounds containing >C = O groups with the same or other compounds containing >C = O groups combined with dehydration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/20—Unsaturated compounds containing keto groups bound to acyclic carbon atoms
    • C07C49/255—Unsaturated compounds containing keto groups bound to acyclic carbon atoms containing ether groups, groups, groups, or groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74—Biological properties of particular ingredients
    • A61K2800/75—Anti-irritant

Definitions

  • the invention relates to a personal care composition comprising selective compounds of the curcuminoid class and to processes to prepare them.
  • the composition of the invention could be delivered in the form of a skin, scalp, hair or oral care product and is especially useful for preventing or reducing inflammation,
  • Inflammation a complicated biological host response to harmful stimuli, is a mechanism by which the host removes the stimuli and initiates the healing process for self-protection.
  • the innate immune system for a host is the first line of defence against invading organisms in a non-specific manner. Dysregulated inflammation may cause various personal care problems including gingivitis/peri odontitis (in the oral cavity), dandruff (on scalp/ hair) and eczema/acnes (on skin).
  • To assist the host organism e.g. the human or animal
  • several anti-inflammatory agents either through topical application or through oral consumption have been developed and used to mitigate the above problems.
  • Acidic drinks and sweets can result in tooth erosion by attacking enamel which is the outer coating that protects the teeth.
  • Foods which are sticky can accumulate in the interstices between teeth and in the region between the gums and the teeth. In the absence of good oral hygiene, these can harden over time with the help of oral bacteria to form a film known as plaque.
  • Gingivitis is an inflammatory process of the gums caused by accumulation of plaque and/or bacteria.
  • gingivitis the bacteria residing in the dental plaque biofilms and its corresponding components interact with gingival tissues. Following this, innate immune response is activated, characterised by the release of pro-inflammatory cytokines.
  • Gingivitis is a mild phase of periodontal disease and defined as reversible inflammation. It is believed that good habit of oral hygiene e.g. brushing and using mouthrinse product with therapeutic anti-microbial and anti-inflammatory efficacy can be an effective way for individuals to reduce the plaque build-up that causes gingivitis. Chronic gingivitis results in mild bleeding from the gums during tooth brushing.
  • Gingivitis can progress to a more severe state (chronic periodontitis) when the inflammatory process extends to the periodontal ligament and alveolar bone and/or exert a significant systemic impact on health.
  • Chronic periodontitis is asymptomatic until teeth shift, loosen, or are lost.
  • Dandruff is a condition experienced by many people worldwide.
  • the dandruff condition varies from mild symptoms such as flaking skin to severe inflammation and itchiness of the scalp.
  • alassezia yeasts such as Malassezia furfur, are believed by some to be the main cause of dandruff and, whilst this might not represent the full scientific picture of the situation, Malassezia yeasts do appear to be closely associated with dandruff.
  • the strategy conventionally used for the treatment of dandruff is the topical application of antifungals such as zinc pyrithione (ZnPTO), octopirox, climbazole and ketoconazole which are normally delivered through a shampoo.
  • antiinflammatory agents have also been used in anti-dandruff products to alleviate the ill- effects of this condition.
  • Acne also known as Acne vulgaris
  • Acne vulgaris is a common skin condition that affects nearly all adolescents and adults at sometimes in their lives. It has a complex etiology, involving abnormal keratinization, excess sebum production, androgen function, bacterial growth, and immune hypersensitivity.
  • one or more of the above processes is correlated with acne, the one triggering factor and the exact sequence of events leading to the formation of acne lesions has not been fully understood.
  • Other factors which have been linked to acne are presence of free radicals with subsequent oxidative stress leading to cellular damage.
  • a bacterium Propionibacterium acnes (P. acnes) has also been implicated in occurrence of acne.
  • Acne has been treated in many ways. Most treatments take several weeks to months before a noticeable change is seen.
  • Benzoyl peroxide which has an antibacterial effect has been used for mild cases of acne and is also believed to prevent formation of further acne.
  • antibiotics like tetracycline, erythromycin and clindamycin have been used.
  • Antibiotics are believed to work by several mechanisms, the most important being the decrease in the number of bacteria in and around the follicle.
  • US2015139973A discloses ophthalmological preparations containing a fatty acid ester and an active agent. Curcumin is disclosed to be an optional ingredient.
  • EP1844786A1 discloses personal care compositions containing dimethoxycurcumin.
  • WO09025315A1 discloses oral compositions for increasing the amount of tetrahydrocurcumin, which is believed to be useful for the maintenance of good health or the amelioration of a disease condition. Specifically disclosed is an oral preparation for improving the bioavailability of a curcumin, which comprises a curcumin and a magnesium salt as active ingredient
  • inflammation is a process that is manifest on the topical surface of the human or animal body in one or all of the above described conditions.
  • the present inventors have attempted to alleviate the symptoms of the above conditions by developing new actives, especially those which could be derivatized from compounds found in extracts of natural materials. Natural materials from which many actives have been extracted include ginger, turmeric, tea, grape, tomato and a host of others.
  • One such active is curcumin which has been known for a long time to alleviate very many health and cosmetic problems.
  • the present inventors have taken curcumin and tried to derivatise it to new compounds hoping to find actives that have anti-inflammatory properties.
  • Curcumin is an active that is extractable from the natural rhizome turmeric. Turmeric has been used as a spice in cooking and has a distinctive yellow colour. It is known to have antimicrobial and anti-inflammatory properties. Curcumin has the structure as give below:
  • curcumin has very many therapeutic properties which enable it to be used in medical and cosmetic treatments, one of the negatives is that it has a strong yellow colour which impedes the flexibility in preparing cosmetic compositions where visual appeal is very important.
  • the present inventors have tried to retain the conjugated double bonds in the curcumin backbone while attempting to minimize the yellowness attribute of the synthesized compound. After extensive experiments involving synthesizing hundreds of such compounds, they arrived at the present invention.
  • a personal care composition in accordance with claim 1.
  • a process to prepare the compound of formula 1 of the first aspect comprising the steps of:
  • Step 2 Compound with formula 3 is di-alkylated to generate compound wit formula 4
  • Step 1 The phenolic hydroxyl groups of curcumin are protected with a suitable protecting group P to generate a compound with formula 5.
  • Step 2 Compound with formula 5 is di-alkylated to generate a compound with formula 6.
  • a method of reducing inflammation on a topical surface of a human or animal body comprising the step of applying the composition of the first aspect on to the desired surface.
  • Oral care composition for the purposes of the present invention means a paste, powder, liquid, gum, serum or other preparation for cleaning the teeth or other surfaces in the oral cavity.
  • “Tooth paste” for the purpose of the present invention means a paste or gel dentifrice for use with a toothbrush. Especially preferred are tooth pastes suitable for cleaning teeth by brushing for about two minutes.
  • “Mouth wash” for the purpose of the present invention means liquid dentifrice for use in rinsing the mouth. Especially preferred are mouth washes suitable for rinsing the mouth by swishing and/or gargling for about half a minute before expectorating.
  • a 'Hair Care Composition is meant to include a composition for topical application to hair and/or scalp of mammals, especially humans. Such a composition may be generally classified as leave-on or rinse off, and includes any product applied to a human body for also improving appearance, cleansing, odor control or general aesthetics.
  • the composition of the present invention can be in the form of a liquid, lotion, cream, foam, scrub, gel, or bar. Non-limiting examples of such compositions include leave-on hair lotions, creams, and wash-off shampoos, conditioners, shower gels, or toilet bar.
  • the composition of the present invention is preferably a wash-off composition, especially preferred being a shampoo or a conditioner and most preferably a shampoo.
  • Water-insoluble refers to the solubility of a material in water at 25°C and atmospheric pressure being 0.1 % by weight or less.
  • topical composition' or a 'skin care composition' as used herein, is meant to include a composition for topical application to the skin of mammals, especially humans.
  • a composition could be of the leave-on or of the wash-off/ rinse-off type.
  • a leave-on composition is meant a composition that is applied to the desired skin surface and left on for a period of time (say from one minute to 24 hours) after which it may be wiped or rinsed off with water, usually during the regular course of personal washing.
  • wash-off/ rinse off composition is meant a composition that is applied to the desired skin surface for a shorter period of time say of the order of seconds or minutes and usually contains sufficient surfactants that aids in cleaning the surface which may be rinsed off with copious amounts of water.
  • the composition may also be formulated into a product which is applied to a human body for improving the appearance, cleansing, odor control or general aesthetics.
  • the composition of the present invention can be in the form of a liquid, lotion, cream, foam, scrub, gel or stick form and may be delivered through a roll-on device or using a propellant containing aerosol can.
  • Skin as used herein is meant to include skin on any part of the body e.g., neck, chest, back, arms, underarms, hands, legs, buttocks and scalp.
  • a class of deodourant product is the so called anti-perspirant (AP) product which contains an AP active which when applied to the axilla of an individual delivers anti-perspirancy and deodourancy benefits.
  • AP anti-perspirant
  • the color of the novel compound of the present invention lies within the colorless to light yellow range for optimum visual appeal and usage in topical and/or skin care compositions.
  • Visual assessment of color from a solid or solution sample of novel compounds in comparison to a solid or solution sample of curcumin provides a means to determine relative reduction of color and appeal potential.
  • UV-Vis spectra of solution samples of novel compounds in comparison to a solution sample of curcumin provides a means to measure color experimentally and allows a more direct measurement of color.
  • the present invention relates to composition comprising a compound of formula 1
  • Ri is OH or OCH 3 ;
  • R 2 is H or CH 3
  • the above compound has a lighter colour compared to the others, especially compound of the formula -3 and curcumin.
  • 3,4-dimethoxybenzaldehyde is condensed with 2,4- pentanedione according to the methods described by Leow, Pay-Chin et al. (European Journal of Medicinal Chemistry (2014) 71 , 67-80) and Cheng, Wei-Feng et al. (Free Radical Biology and Medicine (2006) 40, 526-535) with slight modifications.
  • compound with formula 4 is dissolved in an organic solvent system selected from but not limited to dimethylsulfoxide, N,N- dimethylformamide, N-methylpyrrolidone, methanol, ethanol, isopropanol, t-butanol, t- amyl alcohol, acetone, 2-butanone, chloroform, 1 ,2-dichloroethane, ethyl acetate, isopropyl acetate, isobutyl acetate, acetonitrile, tetrahydrofuran, 2- methyltetrahydrofuran, diethoxymethane, methyl t-butyl ether, water, glycerol, 1 ,2- propanediol and mixtures thereof to generate a biphasic or monophasic system.
  • organic solvent system selected from but not limited to dimethylsulfoxide, N,N- dimethylformamide, N-methylpyrrolidone, methanol, ethanol, isopropano
  • the concentration of compound with formula 3 in the solvent system can range between 0.001 M to 10M, more preferable in the range between 0.01 M to 1 M.
  • a base selected but not limited to an alkali or alkaline earth bicarbonate, carbonate or hydroxide is added, followed by a methylating agent selected from but not limited to iodomethane, bromomethane, chloromethane, dimethylcarbonate, dimethyldicarbonate,
  • the amount of base reagent and methylating agent added can range from 2 to 10 equivalents with respect to the number of formula 3 equivalents, more preferably between 2 to 5 equivalents.
  • a catalyst selected but not limited to quaternary ammonium salts or organic phosphonium salts is added in the range between 0.001 to 1 equivalents with respect to the number of formula 3 equivalents.
  • the reaction may be performed between 10 to 50°C, more preferably between 15 to 35°C but not limited to these temperatures.
  • reaction is monitored by a suitable detection method such as UV-Vis visualization, thin layer chromatography ' and/or high-performance liquid chromatography.
  • a suitable detection method such as UV-Vis visualization, thin layer chromatography ' and/or high-performance liquid chromatography.
  • processing of the reaction mixture to isolate compound of formula 4 involves an extraction process (e.g. dissolving the crude reaction mixture in an organic solvent and washing with aqueous buffers to remove impurities) to isolate the crude product, removal of solvents under reduced pressure between 30 to 65°C, and final purification of the crude product using flash
  • step 1 curcumin is dissolved in an organic solvent system selected from but not limited to dichloromethane, chloroform, 1 ,2-dichloroethane, ethyl acetate, isopropyl acetate, isobutyl acetate, acetonitrile, tetrahydrofuran, 2-methyltetrahydrofuran,
  • organic solvent system selected from but not limited to dichloromethane, chloroform, 1 ,2-dichloroethane, ethyl acetate, isopropyl acetate, isobutyl acetate, acetonitrile, tetrahydrofuran, 2-methyltetrahydrofuran,
  • the concentration of curcumin in the organic solvent can range between 0.001 M to 10M, more preferable in the range between 0.01 to 1 M.
  • a protecting group reagent is added such that when it reacts with the phenolic hydroxyl groups of curcumin it results in the formation of compound with formula 2 where P is the structure of a protecting group covalently attached to the phenolic oxygen atom and further blocks or "protects" the phenolic hydroxyl groups from further reactions during Steps 2 and 3 of the chemical process leading to compound with formula 1.
  • Suitable protecting groups P used in Step 1 include but are not limited to tetrahydropyranyl, 4-methoxytetrahydropyranyl, tetrahydrofuranyl, methoxymethyl, 1 -ethoxyethyl, 1-methyl-1-methoxyethyl, t-butyl, triphenylmethyl, alpha-naphthyldiphenylmethyl, p-methoxyphenyldiphenylmethyl, isopropyldimethylsilyl, t-butyldimethylsilyl, tribe nzylsilyl and triisopropylsilyl.
  • the amount of protecting group reagent added can range from 2 to 50 equivalents with respect to the number of curcumin equivalents, more preferably between 2 to 20 equivalents.
  • a suitable catalyst e.g. acidic such as p-toluenesulfonic acid or weakly basic such as imidazole
  • the reaction can be performed between 10 to 50°C, more preferably between 15 to 35 °C but not limited to these temperatures.
  • the progress of the reaction is monitored by a suitable detection method such as UV-Vis visualization, thin layer chromatography and/or high-performance liquid chromatography.
  • processing of the reaction mixture to isolate compound of formula 5 involves but is not limited to removal of the reaction solvent under reduced pressure between 20 to 55°C, followed by an extraction process (e.g. dissolving the crude reaction mixture in an organic solvent and washing with aqueous buffers to remove impurities) to isolate the crude product, and final purification of the crude product using flash
  • step 2 compound with formula 5 is dissolved in an organic solvent system selected from but not limited to dimethylsulfoxide, ⁇ , ⁇ -dimethylformamide, N-methylpyrrolidone, methanol, ethanol, isopropanol, t-butanol, t-amyl alcohol, acetone, 2-butanone, chloroform, 1 ,2-dichloroethane, ethyl acetate, isopropyl acetate, isobutyl acetate, acetonitrile, tetrahydrofuran, 2-methyltetrahydrofuran, diethoxymethane, methyl t-butyl ether, water, glycerol, 1 ,2-propanediol and mixtures thereof to generate a biphasic or monophasic system.
  • organic solvent system selected from but not limited to dimethylsulfoxide, ⁇ , ⁇ -dimethylformamide, N-methylpyrrolidone, methanol,
  • the concentration of compound with formula 5 in the solvent system can range between 0.001 M to 10M, more preferable in the range between 0.01 M to 1 M.
  • a base selected but not limited to an alkali or alkaline earth bicarbonate, carbonate or hydroxide is added, followed by a methylating agent selected from but not limited to iodomethane, bromomethane, chloromethane, dimethylcarbonate, dimethyldicarbonate, dimethylsulfate, methylfluorosulfonate, methyl methanesulfonate, methyl trifluoromethanesulfonate and trimethyloxonium tetrafluoroborate.
  • Both, the amount of base reagent and methylating agent added can range from 2-10 equivalents with respect to the number of formula 5 equivalents, more preferably between 2-5 equivalents.
  • a catalyst selected but not limited to quaternary ammonium salts or organic phosphonium salts is added in the range between 0.001 -1 equivalents with respect to the number of formula 5 equivalents.
  • the reaction may be performed between 10-50°C, more preferably between 15-35°C but not limited to these temperatures.
  • the progress of the reaction is monitored by a suitable detection method such as UV-Vis visualization, thin layer chromatography and/or high performance liquid chromatography. At the point where no further formation of product is detected the reaction is processed to allow product isolation.
  • processing of the reaction mixture to isolate compound of formula 6 involves an extraction process (e.g. dissolving the crude reaction mixture in an organic solvent and washing with aqueous buffers to remove impurities) to isolate the crude product, removal of solvents under reduced pressure between 30-65°C, and final purification of the crude product using flash
  • step 3 removal of the protecting group P is achieved by dissolving compound with formula 6 in an organic solvent system appropriate and compatible with the conditions needed to remove protecting group P to generate compound with formula 2.
  • solvents applicable in this case include but are not limited to chlorinated solvents (e.g. dichloromethane), alcohols (e.g. ethanol), diols (e.g. 1 ,2- propanediol), triols (e.g.
  • glycerol e.g. tetrahydrofuran, t-butyl methyl ether
  • water esters
  • esters e.g. ethyl acetate
  • dimethylsulfoxide dimethylformamide
  • acetonitrile acetonitrile and mixtures thereof.
  • a suitable deprotection reagent e.g. acidic such as acetic acid or weakly basic such as sodium fluoride
  • the reaction can be performed between 0-50 °C, more preferably between 15-35 °C but not limited to these temperatures.
  • the progress of the reaction is monitored by a suitable detection method such as UV-Vis
  • processing of the reaction mixture to isolate compound of formula 2 involves but is not limited to removal of the reaction solvent under reduced pressure between 20-55 °C, followed by an extraction process (e.g. dissolving the crude reaction mixture in an organic solvent and washing with aqueous buffers to remove impurities) to isolate the crude product, and final purification of the crude product using flash chromatography on silica gel or crystallization using a solvent or mixed solvent system to give pure compound with formula 2.
  • an extraction process e.g. dissolving the crude reaction mixture in an organic solvent and washing with aqueous buffers to remove impurities
  • composition of the invention is an oral care or a skin, scalp or hair care product.
  • the product may be delivered in the form of a solid, soft solid, liquid, emulsion, microemulsion, lotion, cream, gel, or aerosol forms.
  • the personal care composition When the personal care composition is delivered for oral care, it includes a cosmetically acceptable base which may be an abrasive, a thickener, a humectant or an orally acceptable surfactant.
  • a cosmetically acceptable base which may be an abrasive, a thickener, a humectant or an orally acceptable surfactant.
  • the product may be delivered in the form of an ointment, a gel, a dentifrice or a mouthwash.
  • Oral care compositions preferably comprise an abrasive.
  • Gels usually contain silica, whereas opaque creams generally contain calcium based abrasives, especially chalk.
  • Preferred toothpaste compositions have 5 to 60 wt% calcium based abrasive. In more preferred compositions it is 30 to 60 wt% and furthermore preferably from 35 to 55 wt%.
  • Optimal compositions have 40 to 55wt% calcium based abrasive.
  • a preferred abrasive is fine ground natural chalk (FGNC), which is a form of chalk. It is obtained from limestone or marble.
  • FGNC may also be modified chemically or physically by coating during milling or after milling by heat treatment. Typical coating materials include magnesium stearate or oleate.
  • the morphology of FGNC may also be modified during the milling process by using different milling techniques, for example, ball milling, air-classifier milling or spiral jet milling.
  • FGNC may be used as the sole calcium based abrasive. However, FGNC may also be used with the other calcium based abrasives for some balance of abrasion.
  • the particle size of chalk is from 1 to 60 ⁇ , and preferred sizes range from 1 to 15 pm.
  • DCP dicalcium phosphate
  • PCC precipitated calcium carbonate
  • FGNC is 35 to 100%, more preferably 75 to 100% and especially from 95 to 100% of the total amount of Calcium based abrasives.
  • the balance most preferably, is PCC.
  • abrasives may also be used depending upon the intended degree of abrasion. These include synthetic abrasive polishing agents such as amorphous precipitated silica and silica gels. Other abrasive agents include magnesium carbonate, sodium metaphosphate, potassium metaphosphate, zirconium silicate, potassium
  • metaphosphate magnesium orthophosphate
  • tricalcium phosphate magnesium orthophosphate
  • trimagnesium phosphate aluminum silicate, zirconium silicate and perlite.
  • the composition comprises a thickener.
  • Thickeners that may be used in this invention include, sodium carboxymethyl cellulose (SCMC), hydroxyl ethyl cellulose, methyl cellulose, ethyl cellulose, gum tragacanth. gum arabic, gum karaya, xanthan gum, sodium alginate, carrageenan gum, guar gum, Irish moss, starch, modified starch, silica based thickeners including silica aerogels, magnesium aluminum silicate (e.g., Veegum), Carbomers (cross-linked acrylates) and mixtures thereof.
  • SCMC sodium carboxymethyl cellulose
  • hydroxyl ethyl cellulose hydroxyl ethyl cellulose
  • methyl cellulose methyl cellulose
  • ethyl cellulose gum tragacanth.
  • gum arabic gum karaya
  • xanthan gum sodium alginate
  • carrageenan gum guar gum
  • Irish moss starch
  • thickening silica, sodium carboxymethyl cellulose and/or a Carbomer is/are preferred thickeners for use in the composition of the invention.
  • a Carbomer those having a weight-average molecular weight of at least 700,000 are desired, and preferably, those having a molecular weight of at least 1 ,200,000, and most preferably, those having a molecular weight of at least about 2,500,000 are desired.
  • Mixtures of Carbomers may also be used herein.
  • the Carbomer is Synthalen PNC, Synthalen KP or a mixture thereof. It has been described as a high molecular weight and cross- linked polyacrylic acid and identified via CAS number 9063-87-0. These types of materials are available commercially from suppliers like Sigma.
  • the sodium carboxymethyl cellulose (SCMC) used is SCMC 9H. It has been described as a sodium salt of a cellulose derivative with carboxymethyl groups bound to hydroxy groups of glucopyranose backbone monomers and identified via CAS number 9004-32-4. The same is available from suppliers like Alfa Chem.
  • Thickening silica is especially preferred to be used in gel toothpastes.
  • Gel toothpastes generally contain upto 8.5 wt% thickening silica whereas opaque toothpastes typically contain 3 to 4 wt% thickening silica.
  • preferred thickening silicas include AEROSIL T series from Degussa or the CAB-O-S!L series from Cabot Corporation, silica gels such as the SYLODENT or SYLOX series from W. R.Grace & Co or precipitated silica such as ZEOTHIX 265 from J. M. Huber Corporation.
  • Useful silica thickeners also include ZEODENT 165, ZEODENT 163 and/or 167 and ZEOFREE 153, 177, and/or 265 silicas, all available from J. M. Huber Corporation.
  • Other preferred thickening silicas include MFIL, MFIL-P (From Madhu Silica, India), SIDENT 22 S and AEROSIL 200 (Ex.
  • Thickener when present, preferably makes up from 0.01 to about 10%, more preferably from 0.1 to 9%, and most preferably, from 1.5 to 8% by weight of the composition.
  • Suitable humectants are preferably used in the oral care composition of the present invention and they include, for example, glycerin, sorbitol, propylene glycol, dipropylene glycol, diglycerol, triacetin, mineral oil, polyethylene glycol (preferably, PEG-400), alkane diols like butane diol and hexanediol, ethanoi, pentylene glycol, or a mixture thereof. Glycerin, polyethylene glycol, sorbitol or mixtures thereof are the preferred humectants.
  • the humectant may be present in the range of from 10 to 90% by weight of oral care compositions.
  • the humectant makes up from 25 to 80%, and most preferably, from 45 to 70% by weight of the composition, based on total weight of the composition and including all ranges subsumed therein.
  • an oral care composition comprises a surfactant.
  • composition comprises at least 0.01 % surfactant by weight of the composition, more preferably at least 0.1% and most preferably from 0.5 to 7%.
  • Suitable surfactants include anionic surfactants, such as the sodium, magnesium, ammonium or ethanolamine salts of C8 to C18 alkyl sulphates (for example sodium lauryl sulphate), C8 to C18 alkyl sulphosuccinates (for example dioctyl sodium sulphosuccinate), C8 to C18 alkyl sulphoacetates (such as sodium lauryl sulphoacetate), C8 to C18 alkyl sarcosinates (such as sodium lauryl sarcosinate), C8 to C18 alkyl phosphates (which can optionally comprise up to 10 ethylene oxide and/or propylene oxide units) and sulphated monoglycerides.
  • anionic surfactants such as the sodium, magnesium, ammonium or ethanolamine salts of C8 to C
  • the surfactant comprises or is an anionic surfactant.
  • the preferred anionic surfactants are sodium lauryl sulphate and/or sodium dodecylbenzene sulfonate. Most preferably the surfactant is sodium lauryl sulphate.
  • Other suitable surfactants include nonionic surfactants, such as optionally
  • surfactants include amphoteric surfactants, such as betaines or sulphobetaines. Mixtures of any of the above described materials may also be used. Most preferred surfactants are an alkali metal alkyl sulphate or a betaine.
  • Water may preferably be included in 5 to 95%, in particular, 10 to 75%, and especially at from 10 to 60%, furthermore preferably 10 to 45% by total weight of the composition.
  • the oral care composition of this invention is a toothpaste or gel
  • the same typically has a viscosity from about 30,000 to 180,000 centipoises, and preferably, from 60,000 to 170,000 centipoises, and most preferably, from 65,000 to 165,000 centipoises.
  • the oral care composition of the present invention may contain a variety of other ingredients which are common in the art to enhance physical properties and performance. These ingredients include antimicrobial, anti-caries agents, plaque buffers, fluoride sources, vitamins, plant extracts, desensitizing agents, anti-calculus agents, biomolecules, flavors, proteinaceous materials, preservatives, opacifying agents, coloring agents, pH-adjusting agents, sweetening agents, particulate abrasive materials, polymeric compounds, buffers and salts to buffer the pH and ionic strength of the compositions, and mixtures thereof. Such ingredients typically and collectively make-up less than 20% by weight of the composition, and preferably, from 0.0 to 15% by weight, and most preferably, from 0.01 to 12% by weight of the composition, including all ranges subsumed therein.
  • the composition may be used for hair care. It is especially useful for preventing or alleviating the symptoms of dandruff.
  • One medium through which this may be delivered is that of a shampoo.
  • the composition of the invention especially shampoos are formulated with an anionic surfactant e.g. an alkyl sulphate and/or ethoxylated alkyl sulfate surfactant. These anionic surfactants are preferably present at a level of from 1 to 20%, preferably 2 to 16%, furthermore preferably from 3 to 16% by weight of the composition.
  • Preferred alkyl sulfates are C8- 18 alky sulfates, more preferably C12-18 alkyl sulfates, preferably in the form of a salt with a solubilising cation such as sodium, potassium, ammonium or substituted ammonium.
  • Preferred alkyl ether sulfates are those having the formula: RO(CH 2 CH?0) n S0 3 M; wherein R is an alkyl or alkenyl having from 8 to 18 (preferably 12 to 18) carbon atoms; n is a number having an average value of greater than at least 0.5, preferably between 1 and 3, more preferably between 2 and 3, and M is a solubilising cation such as sodium, potassium, ammonium or substituted ammonium.
  • SLES sodium lauryl ether sulfate
  • Preferred ethoxylated alkyl sulfate anionic surfactant is sodium lauryl ether sulfate (SLES). SLES having an average degree of ethoxylation of from 0.5 to 3, preferably 1 to 3 is especially preferred.
  • Shampoo compositions according to the invention may comprise one or more further anionic cleansing surfactants which are cosmetically acceptable and suitable for topical application to the hair.
  • a composition of the invention preferably additionally comprises an amphoteric surfactant preferably a betaine surfactant preferably an alkyl amidopropyl betaine surfactant for example cocamidopropyl betaine.
  • the composition comprises from 0,1 to 10 wt.%, preferably from 0.5 to 8 wt.%, more preferably from 1 to 5 wt.% of a betaine surfactant
  • cationic polymers are generally included therein.
  • the composition additionally includes 0.01 to 2.0% of a cationic polymer.
  • the cationic polymer is preferably guar hydroxypropyl trimonium chloride.
  • Guar polymer predominantly contains galactomannan polymer chains. This polymer is available at various molecular weights and degree of cationic substitutions depending on how much the guar has been hydrolysed and cationised.
  • the cationic polymer is preferably present in 0.04 to 0.5%, more preferably 0.08 to 0.25% by weight of the composition.
  • the composition is called a hair conditioner.
  • the most popular conditioning agents used in hair care compositions are water-insoluble oily materials such as mineral oils, naturally occurring oils such as triglycerides and silicone polymers.
  • Conditioning benefit is achieved by the oily material being deposited onto the hair resulting in the formation of a film, which makes the hair easier to comb when wet and more manageable when dry.
  • An especially useful conditioning agent is a silicone compound, preferably a non-volatile silicone compound.
  • Advantageously compositions herein may include one or more silicones.
  • the silicones are conditioning agents found in dispersed or suspended particulate form. They are intended to deposit onto hair remaining behind after rinsing of the hair with water.
  • Suitable silicone oils may include polyalkyl siloxanes, polyaryl siloxanes, polyalkylaryl siloxanes, polyether siloxane copolymers and mixtures thereof. Amino silicones are often formulated with shampoo compositions.
  • Amino silicones are silicones containing at least one primary amine, secondary amine, tertiary amine or a quaternary ammonium group. High molecular weight silicone gums can also be utilized. Another useful type are the crosslinked silicone elastomers such as DimethiconeA/inyl/D ' imethicone Crosspolymers (e.g. Dow Corning 9040 and 9041). Amounts of the silicone in compositions where present may range from about 0.1 to about 10 wt.%, preferably from about 0.1 to about 8wt.%, more preferably from about 0.3 to about 5wt.% by weight of the hair care compositions. The pH of the composition is preferably equal to or higher than 4.0, more preferably in the range of 5.0 to 7.0.
  • the hair conditioning composition usually comprises conditioning surfactants selected from cationic surfactants, used singly or in admixture.
  • conditioning surfactants selected from cationic surfactants, used singly or in admixture.
  • Suitable cationic surfactants for use in conditioner compositions according to the invention include
  • cetyltrimethylammonium chloride behenyltrimethylammonium chloride, cetylpyridinium chloride, tetramethylammonium chloride, tetraethylammonium chloride,
  • hexadecyltrimethylammonium chloride octyldimethylbenzylammonium chloride, decyldimethylbenzylammonium chloride, stearyldimethylbenzylammonium chloride, didodecyldimethylammonium chloride, dioctadecyldimethylammonium chloride, tailowtrimethylammonium chloride, dihydrogenated tallow dimethyl ammonium chloride (eg. Arquad 2HT/75 from Akzo Nobel), cocotrimethylammonium chloride, PEG-2- oleammonium chloride and the corresponding hydroxides thereof.
  • Suitable cationic surfactants include those materials having the CTFA designations Quaternium- 5, Quaternium-31 and Quaternium-18. Mixtures of any of the foregoing materials may also be suitable.
  • a particularly useful cationic surfactant for use in conditioners according to the invention is cetyltrimethylammonium chloride, available commercially, for example as GENAMIN CTAC, ex Hoechst Celanese.
  • Another particularly useful cationic surfactant for use in conditioners according to the invention is
  • behenyltrimethylammonium chloride available commercially, for example as
  • stearamidopropyl dimethylamine The most preferred cationic surfactants for use in the composition are
  • the level of cationic surfactant will generally range from 0.1 % to 5%, preferably 0.5 to 2.5% by weight of the composition.
  • Hair conditioning compositions of the invention preferably may also additionally comprise a fatty alcohol. The combined use of fatty alcohols and cationic surfactants in conditioning compositions is believed to be especially advantageous, because this leads to the formation of a lamellar phase, in which the cationic surfactant is dispersed.
  • Representative fatty alcohols comprise from 8 to 22 carbon atoms, more preferably 16 to 22.
  • Fatty alcohols are typically compounds containing straight chain a Iky I groups.
  • suitable fatty alcohols include cetyl alcohol, stearyl alcohol and mixtures thereof. The use of these materials is also advantageous in that they contribute to the overall conditioning properties of compositions of the invention.
  • the level of fatty alcohol in conditioners of the invention will generally range from 0.5 to 10%, preferably from 0.1 % to 8%, more preferably from 0.2 % to 7 %, most preferably from 0.3 % to 6 % by weight of the composition.
  • the weight ratio of cationic surfactant to fatty alcohol is suitably from 1 :1 to 1 :10, more preferably from 1 : 1.5 to 1 :8, optimally from 1 :2 to 1 :5.
  • Hair care compositions whether delivered as shampoos or conditioners usually comprise an anti-dandruff agent.
  • the most preferred anti-dandruff agent for use in the compositon of the invention is a zinc based anti-dandruff agent preferably zinc pyrthione.
  • Zinc pyrithione belongs to the class of insoluble metal pyrithione which may be represented by the following general formula:
  • M is a polyvalent metal ion and n corresponds to the valency of M.
  • M corresponds to Zinc and n has the value of 2.
  • the zinc pyrithione may have any particle form suitable for use in a composition for topical application.
  • the zinc pyrithione may be in the form of amorphous or crystalline particles having a range of different particle sizes.
  • the zinc pyrithione may, for example, be in the form of particles having a size distribution in which at least about 90% of the particles have a size of up to 100 microns, more preferably up to 50 microns, even more preferably up to 10 microns, most preferably 5 microns or less.
  • the insoluble metal pyrithione may be made up of one particulate form or two or more different particulate forms.
  • Suitable particulate forms for the zinc pyrithione include platelets and needle- shaped particles.
  • Platelets of zinc pyrithione are described in EP-A-0034385, the contents of which are incorporated herein by reference.
  • the needle-shaped particles are preferably of the type described in W099/66886, the contents of which are incorporated herein by reference.
  • For needle-shaped particles preferably at least 50% by number of the particles are needle-shaped particles having a length of between 1 ⁇ and 50 ⁇ ).
  • the amount of metal pyrithione incorporated into the compositions may depend on the type of composition and the exact nature of the material used.
  • a preferred amount of pyrithione is from about 0.01 % to about 1.5% by weight of the total composition, more preferably from about 0.05% to about 1 5% by weight of the total composition.
  • the composition as per the invention especially for anti-dandruff shampoos preferably additionaliy comprises a zinc compound.
  • additional zinc compound in the composition is believed to improve the antidandruff efficacy of the zinc based antidandruff agent.
  • Suitable zinc compounds are zinc oxide, zinc citrate, zinc malonate, zinc carbonate or combinations thereof.
  • the zinc compound is preferably present in 0.1 to 3%, more preferably 0.1 to 1.5% by weight of the composition.
  • Shampoo composition as per the invention preferably additionally comprises a conazole fungicide.
  • the conazole fungicide is selected form ketoconazole, climbazole or mixtures thereof.
  • the azole fungicide is preferably included in 0.01 to 2%, more preferably 0.025 to 0.75% by weight of the composition. The presence of a conazole fungicide is believed to improve the deposition of zinc pyrithione.
  • the composition of the invention may be used for skin care.
  • the cosmetically acceptable base in such cases may be a liquid or solid material.
  • base is present in an amount ranging from 10 to 99.9%, more preferably from 20 to 95%, most preferably from 40 to 85% by total weight of the composition including all ranges subsumed therein.
  • the cosmetically acceptable carrier includes water. Water is preferably included in an amount from 30 to 90%, more preferably from 30 to 85%, most preferably from 30 to 80% by total weight of the sunscreen composition.
  • suitable carrier classes include silicones, polyhydric alcohols, hydrocarbons, triglycerides and thickening powders.
  • the skin care composition of the invention may be in any form including toners, lotions, creams, mousses, scrub, serum or gel that is suitable for topical application to the skin.
  • the composition can be either a leave-on product such as skin lotions, creams, antiperspirants, deodorants, lipsticks, foundations, mascara, sunless tanners and sunscreen lotions or a rinse-off product such as shower gels and toilet bars. It is preferred that the composition is a skin lotion or a cream.
  • the composition may comprise an emollient oil that act as a co-solvent.
  • Suitable emollient oils include, for example, ester of alkoxylated aromatic alcohol with fatty carboxylic acid, esters of polyglycols or diols with fatty carboxylic acid such as caprylic/capric triglyceride, ester of fatty alcohol and fatty acid, alkoxylated derivative of benzyl alcohol and mixtures thereof.
  • the emollient oil is caprylic/capric triglyceride.
  • compositions comprise co-solvent in an amount from 0.01 to 10%, more preferably from 0.1 to 8%, most preferably from 1 to 6%, based on the total weight of the sunscreen composition and including all ranges subsumed therein.
  • the composition may additionally comprise sunscreen agents such as inorganic sunscreens.
  • sunscreen agents such as inorganic sunscreens.
  • sunscreen agents such as inorganic sunscreens.
  • zinc oxide, titanium dioxide, iron oxide, silica such as fumed silica.
  • the amount of such sunscreen agents is preferably incorporated from 0.1 to 5% by total weight of the sunscreen composition.
  • the composition of the invention may comprise a UV-A sunscreen agent selected from the group consisting of a dibenzoylmethane derivative, a triazine derivative, a benzophenone derivative and mixtures thereof.
  • the UV-A sunscreen agent comprises or is a dibenzoylmethane derivative, for example, butyl methoxydibenzoylmethane (sold under the trade name Parsol 1789).
  • the sunscreen composition of the present invention comprises from 0.1 to 15% by weight of the UV-A sunscreen agent, more preferably from 0.1 to 10%, most preferably from 1 to 5%, based on the total weight of the composition and including all ranges subsumed therein.
  • composition of the invention may also comprise a UV-B sunscreen agent.
  • Suitable UV-B sunscreen agent of the invention is selected from the group consisting of a benzophenone, an anthranilate, a salicylate, a cinnamate, a camphor, benzylidene malonate, a triazone, and derivatives thereof.
  • the UV-B sunscreen agent comprises or is a cinnamate derivative, for example, ethylhexyl methoxycinnamate (sold under the trade name Parsol MCX).
  • the composition comprises from 0.1 to 20% by weight of the UV-B sunscreen agent, more preferably from 0.5 to 18%, most preferably from 1 to 15%, based on the total weight of the composition and including all ranges subsumed therein.
  • a skin lightening agent may also be incorporated into the composition of the invention.
  • Most preferred skin lightening active is a Vitamin B3 compound.
  • Vitamin B3 compound maybe nicacin, nicotinic acid or niacinamide, preferably niacinamide.
  • Niacinamide has the structure given below:
  • Niacinamide is preferably present in 0.01 to 5%, more preferably 0.1 to 3% by weight of the composition.
  • Suitable skin lightening agents other than Vitamin B3 and its derivatives are kojic acid, arbutin, tranexamic acid, placental extract, ascorbic acid and its derivatives (e.g.
  • the skin lightening agent is present in an amount from 0.1 to 10%. More preferably from 0.2 to 5%, most preferably from 0.3 to 3% by total weight of the composition including all ranges subsumed therein.
  • a specific class of skin care compositions is what is known as deodourant
  • compositions can be applied cosmetically and topically to the skin, broadly speaking, by one of two methods. Different consumers prefer one method or the other. In one method, sometimes called a contact method, a composition is wiped across the surface of the skin, depositing a fraction of the composition as it passes. In the second method, sometimes called the non-contact method, the composition is sprayed from a dispenser held proximate to the skin, often in the region of 10 to 20 cms.
  • the spray can be developed by mechanical means of generating pressure on the contents of the dispenser, such as a pump or a squeezable sidewall or by internally generated pressure arising from a fraction of a liquefied propellant volatilising, the dispenser commonly being called an aerosol.
  • the carrier fluid comprises a solvent for the desired active and in a second variation, the active remains as a particulate solid that is suspended in an oil, usually a blend of oils.
  • gellant for a continuous oil phase
  • materials including waxes, small molecule gelling agents and polymers. They each have their advantages and of them, one of the most popular class of gellant has comprised waxes, partly at least due to their ready availability and ease of processing, including in particular linear fatty alcohol wax gellants.
  • a gelled deodourant composition is applied topically to skin by wiping it across and in contact with the skin, thereby depositing on the skin a thin film. The nature of the film depends to a significant extent on the gellant that is employed.
  • wax fatty alcohols have been employed as gellant for many years, and are effective for the purpose of gelling, the resultant product is rather ineffective at improving the visual appearance of skin, and in particular underarm skin, to which the composition has been applied. This problem has been solved by including
  • ameliorating materials for example, di or polyhydric humectants and/or a triglyceride oil.
  • Roll-on Liquid compositions that are applicable from a roll-on broadly speaking can be divided into two classes, namely those in which an active is suspended in a hydrophobic ⁇ carrier, such as a volatile silicone and those in which the active is dissolved in a carrier liquid. The latter has proven to be more popular.
  • a hydrophobic ⁇ carrier such as a volatile silicone
  • carrier liquid There are mainly two sorts of dissolving carrier liquid, namely carriers that are predominantly alcoholic, which is to say the greater part of the dissolving carrier fluid comprises ethanol and the second class in which the carrier liquid is mainly water.
  • the former was very popular because ethanol is a mild bactericide in its own right, but its popularity waned because it stings, especially if the surface onto which the composition has been applied has been damaged or cut, such as can easily arise during shaving or other de-hairing operations.
  • the second class of formulations that is an alternative to alcoholic formulations comprise a dispersion of water-insoluble or very poorly water-soluble ingredients in an aqueous solution of the active.
  • emulsions Such compositions will be called emulsions.
  • Roll-on emulsions commonly comprise one or more emulsifiers to maintain a distribution of the water-soluble ingredients.
  • Deodourant compositions may be delivered through an aerosol which comprises a propellant in addition to the other ingredients described hereinabove.
  • the propellant is employed in a weight ratio to the base formulation of from 95:5 to 5:95.
  • the ratio of propellant to base formulation is normally at least 20:80, generally at least 30:70, particularly at least 40:60, and in many formulations, the weight ratio is from 90: 10 to 50:50.
  • a ratio range of from 70:30 to 90:10 is sometimes preferred.
  • Propellants herein generally accord with one of three classes; i) low boiling point g asses liquefied by compression, ii) volatile ethers and iii) compressed non-oxidising gases.
  • Class i is conveniently a low boiling point material, typically boiling below -5°C, and often below -15°C, and in particular, alkanes and/or halogenated hydrocarbons.
  • This class of propellant is usually liquefied at the pressure in the aerosol canister and evaporates to generate the pressure to expel the composition out of the canister.
  • suitable alkanes include particularly propane, butane or isobutene.
  • the second class of propellant comprises a very volatile ether of which the most widely employed ether hitherto is dimethyl ether.
  • This propellant can advantageously be employed at relatively low weight ratio of propellant to base formulation, for example to as low as 5:95. It can also be employed in admixture with, for example,
  • the third class of propellant comprises compressed non-oxidising gasses, and in particular, carbon dioxide or nitrogen. Inert gases like neon are a theoretical alternative.
  • Skin care compositions may also comprise other ingredients which are common in the art to enhance physical properties and performance. Suitable ingredients include but are not limited to humectants, thickeners, opacifiers, binders, colorants and pigments, pH adjusting agents, preservatives, optics, perfumes, viscosity modifiers, biological additives, buffering agents, conditioners, natural extracts, essential oils and skin benefit agents including anti-inflammatory agents, cooling agents, antiperspirant agents, anti- aging agents, anti-acne agents, anti-mi crobial agents and antioxidants.
  • the invention provides for a method of reducing inflammation on a topical surface of a human or animal body comprising the step of applying the composition of the invention on to the desired surface.
  • the method is preferably non-therapeutic.
  • the method may comprise applying the composition as a leave-on composition. Leave-on compositions are applied on to the desired skin surface and left thereon till the person washes the skin during the normal course of personal washing e.g. when showering or during a bath.
  • the composition may a wash -off composition where it is used to clean the body surface and this type of composition includes a soap bar, a body wash or face wash composition or shampoo or hair conditioning composition.
  • this type of composition includes a soap bar, a body wash or face wash composition or shampoo or hair conditioning composition.
  • THP1-XBIueTM (Cat No: thpx-sp, InvivoGen) cells were cultured as suspense in RPMI 1640 medium supplemented with 10% FBS, penicillin (10 U/mL) - streptomycin (10 pg/ML). Cells were differentiated in 24-well plates at the density of 5 x 10 5 cells / well with 100 nM PMA for 72 h. Cells were then co-treated with pure E. coli
  • LPS lipopolysaccharides
  • IL-6 interleukin-6 as pro-inflammatory bio-marker using enzyme- linked immunosorbent assay (ELISA).
  • Examples 4 to 7 Anti-inflammation efficacy of compound of formula 1 using Human Gingival Fibroblasts assay
  • Primary human gingival fibroblasts HGFs, Cat No. 2620, ScienCellTM
  • FBS fetal bovine serum
  • 5 ml_ of fibroblast growth supplement 5 ml.
  • HGFs penicillin/streptomycin solution (Cat No. 2301 , ScienCellTM). HGFs were seeded in 24 well-plates at the density of 2 x 10 4 cells / well and cultured for 72 h. Cells were pre- incubated with active for 2 h. After removal of the active medium, the cells were washed with PBS and further treated with heat-inactivated P. gingivalis (Cat. 33277, ATCC). After 4 h, the supernatants were collected and measured for IL-6, IL-8 and monocyte chemoattractant protein (MCP) -1 as pro-inflammatory bio-markers using ELISA. The data is summarised in Table - 2 below:
  • Table 1 and 2 indicate the anti-inflammatory efficacy of compounds of the invention which is applicable over a wide range of personal care products.
  • Table 2A Further data pertaining to inhibition of IL-6, IL-8 and MCP-1 is shown in Table 2A below. Table 2A
  • TLC thin layer chromatography
  • Liquid chromatography/mass spectrometry was performed using a Finnigan Mat LCQ Mass Spectrometer via direct infusion of samples (50ppm) in methanol and the total ion count monitored using electrospray ionization in the (+) or (-) mode (ESI+) or (ESI-).
  • Step 1 Condensation of 3,4-dimethoxybenzaldehvde with 2.4-pentanedione to generate compound with formula 3 (1 E,6E)-1 ,7-bis(3,4-dimethoxvphenv0hepta-1 ,6- diene-3,5-dione:
  • 2,4-Pentanedione (3g, 30.0 mmol) and boric anhydride (1.46g, 21.0 mmol) were dissolved in ethyl acetate (EA) (30 ml) and heated at 45 °C for 30 min.
  • EA ethyl acetate
  • 3,4- Dimethoxybenzaldehyde (9.96g, 59.9mmol) and tributylborate (13.79 g, 59.9 mmol) were added and the mixture stirred at 45 °C for 30 min.
  • Butylamine (4.44 ml, 44.9 mmol) in EA (30 ml) was added dropwise over 15 min and the solution stirred at 45 °C for 16 hr.
  • Aqueous HCI (prepared by adding 4.5 ml cone. HCI to 25.5 ml water) was added and the biphasic mixture stirred and heated at 60 °C for 1 h. The layers were separated and the aqueous layer extracted with EA (50 ml). The combined organic layers were washed with water, saturated NaCI, dried with Na 2 S04, filtered and the solvents removed under reduced pressure to give crude product as a red oil (10.42 g). The crude product was purified by FC on silica gel eluting with EA:hexane (50:50) to give pure product of formula 3 as a yellow oil which crystallized upon standing as an orange solid (4.0 g, 34%). HPLC-UV showed >97% purity.
  • Step 2 Di-methylation of compound with formula 3 to generate compound with formula 4 (1 E,6E)-1 J-bis(3,4-dimethoxyphenyl)-4,4-dimethylhepta-1 ,6-diene-3,5-dione:
  • Step 1 Protection of the phenolic hydroxy! groups of curcumin to generate compound with formula 5a (1 E.6E)-1.7-bis(3-methoxv-4-((tetrahydro-2H-pvran-2- yl)oxv)phenyl)hepta-1 ,6-diene-3.5-dione: Pyridinium p-toluenesulfonate (PPTS) (512 mg, 2.03 mmol) was added to a solution of curcumin (5 g, 13.6 mmol) and dihydropyran (DHP) (37.2 ml, 407 mmol) in anhydrous dichloromethane (DCM) (300 ml) and the solution stirred at room temperature (25 °C) overnight for 6 h.
  • PPTS Pyridinium p-toluenesulfonate
  • DHP dihydropyran
  • Step 2 Di-methylation of compound with formula 5a to generate compound with formula 6a (1 E,6E)-1.7-bis(3-methoxv-4-((tetrahydro-2H-pvran-2-vl ' ) oxv)phenvl)- .4- dimethylhepta-1 ,6-diene-3,5-dione: Potassium carbonate (K 2 C0 3 ) (3.86 g, 27.9 mmol) was added to a solution of (1 E.6E)- 1 ,7-bis(3-methoxy-4-((tetrahydro-2H-pyran-2-yl) oxy)phenyl)hepta-1 ,6-diene-3,5-dione (3 g, 5.59 mmol) in anhydrous dimethylsulfoxide (D SO) (9 ml), followed by iodomethane (Mel) (1.74 ml, 27.9 mmol) and the mixture stirred at room temperature
  • Step 3 Deprotection of the phenoxide groups of compound with formula 6a to generate compound with formula 2 (1 E.6E)-1.7-bis(4-hvdroxv-3-methoxyphenvl) ⁇ 4.4- dimethylhepta-1 ,6-diene-3.5-dione:
  • Figures 1 to 4 show the UV-Vis spectrum of compounds with formula 1 and curcumin obtained from HPLC analysis of 1 mg/ml solution of each compound and using a photodiode array detector.
  • UV-Vis spectra of compounds with formulas 2 and 4 are consistent with their significant reduction in color compared to curcumin (orange - . max ⁇ 426 nm).
  • the UV-Vis spectrum of compound with formula 3 is comparable to curcumin's spectrum and also consistent with its orange color.
  • HEKa Primary adult human keratinocytes frozen at passage 1 were purchased from Invitrogen (Cat no C0055C). They were thawed into KGM Gold (Lonza cat no
  • the cell pellet was re-suspended in KGM Gold plus 70 ⁇ calcium and containing the bullet kit components but omitting the gentamycin and hydrocortisone (referred to as plating medium).
  • the cells were plated into 24-well plates at a density of 2x10 4 cells/well and allowed to settle for 24 hours prior to treatment.
  • the medium was removed from the cells and replaced by 0.5ml plating medium containing 200ug/ml IL-17, 200ug/ml IL-22 and 10ug/ml TNFa together with the active at the required concentration. Also included are an untreated control, a vehicle control and a triple cytokine mix without active all in triplicate. The plates are incubated for a further 16 to 24 hours. The medium was harvested for IL-8 ELISA and the cells lysed for protein assay (Pierce BCA Protein Assay Kit Life Technologies cat no 23225) in order to normalise IL-8 to protein. The data is tabulated in Table-4. Table 4

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Rheumatology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Birds (AREA)
  • Cosmetics (AREA)

Abstract

L'invention concerne une composition de soins personnels comprenant un composé de la classe des curcuminoïdes et un procédé de préparation de celle-ci. Il a été démontré qu'elle présente un effet bénéfique anti-inflammatoire et peut être utilisée dans une large gamme de produits de soins personnels, tout en ne présentant pas la forte coloration jaune qui est caractéristique de nombreux composés de cette classe.
PCT/EP2017/077327 2016-10-27 2017-10-25 Composition de soins personnels comprenant des curcuminoïdes Ceased WO2018077958A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CNPCT/CN2016/103527 2016-10-27
CN2016103527 2016-10-27
EP16201713.1 2016-12-01
EP16201713 2016-12-01

Publications (1)

Publication Number Publication Date
WO2018077958A1 true WO2018077958A1 (fr) 2018-05-03

Family

ID=60262908

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2017/077327 Ceased WO2018077958A1 (fr) 2016-10-27 2017-10-25 Composition de soins personnels comprenant des curcuminoïdes

Country Status (1)

Country Link
WO (1) WO2018077958A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020212098A1 (fr) 2019-04-15 2020-10-22 Unilever Plc Composition de soins d'hygiène personnelle comprenant de la tétraméthylcurcumine et procédé de production de la composition
CN118476975A (zh) * 2024-05-08 2024-08-13 广州环亚化妆品科技股份有限公司 四甲基姜黄素在美白方面的应用
US12447119B2 (en) 2019-03-18 2025-10-21 Sunstar Americas, Inc. Oral care composition

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0034385A2 (fr) 1980-02-07 1981-08-26 THE PROCTER & GAMBLE COMPANY Sels de pyridinethione et de zinc, procédé pour leur préparation et produits capillaires les contenant
EP0173259A2 (fr) 1984-08-29 1986-03-05 Kao Corporation Suspensions antimicrobiennes et compositions antimicrobiennes pour le traitement de la chevelure
WO1999066886A1 (fr) 1998-06-24 1999-12-29 Unilever Plc Composition antimicrobienne de traitement capillaire
JP2005029571A (ja) * 2003-06-16 2005-02-03 Yoshiyuki Mizushina ＤＮＡ合成酵素λ阻害作用を有する化合物とその利用
US20060258752A1 (en) * 2004-02-12 2006-11-16 Vander Jagt David L Method and compounds for cancer treatment utilizing NFkB as a direct or ultimate target for small molecule inhibitors
EP1844786A1 (fr) 2006-04-03 2007-10-17 Exsymol S.A.M. Extrait de curcuma longa et ses applications cosmétiques ou dermopharmaceutiques
WO2009025315A1 (fr) 2007-08-21 2009-02-26 Kyowa Hakko Bio Co., Ltd. Préparation orale pour l'amélioration de la biodisponibilité de la curcumine
US20120053208A1 (en) 2009-04-15 2012-03-01 The Ohio State University Research Foundation Curcumin Analogs as Dual JAK2/STAT3 Inhibitors and Methods of Making and Using the Same
US20150139973A1 (en) 2012-05-15 2015-05-21 F. Holzer Gmbh Ophthalmological vehicle system for drugs, ophthalmological kit and also use of an ophthalmological composition
CN105348219A (zh) * 2014-08-22 2016-02-24 沈阳药科大学 姜黄素类似物及其制备和应用

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0034385A2 (fr) 1980-02-07 1981-08-26 THE PROCTER & GAMBLE COMPANY Sels de pyridinethione et de zinc, procédé pour leur préparation et produits capillaires les contenant
EP0173259A2 (fr) 1984-08-29 1986-03-05 Kao Corporation Suspensions antimicrobiennes et compositions antimicrobiennes pour le traitement de la chevelure
WO1999066886A1 (fr) 1998-06-24 1999-12-29 Unilever Plc Composition antimicrobienne de traitement capillaire
JP2005029571A (ja) * 2003-06-16 2005-02-03 Yoshiyuki Mizushina ＤＮＡ合成酵素λ阻害作用を有する化合物とその利用
US20060258752A1 (en) * 2004-02-12 2006-11-16 Vander Jagt David L Method and compounds for cancer treatment utilizing NFkB as a direct or ultimate target for small molecule inhibitors
EP1844786A1 (fr) 2006-04-03 2007-10-17 Exsymol S.A.M. Extrait de curcuma longa et ses applications cosmétiques ou dermopharmaceutiques
WO2009025315A1 (fr) 2007-08-21 2009-02-26 Kyowa Hakko Bio Co., Ltd. Préparation orale pour l'amélioration de la biodisponibilité de la curcumine
US20120053208A1 (en) 2009-04-15 2012-03-01 The Ohio State University Research Foundation Curcumin Analogs as Dual JAK2/STAT3 Inhibitors and Methods of Making and Using the Same
US20150139973A1 (en) 2012-05-15 2015-05-21 F. Holzer Gmbh Ophthalmological vehicle system for drugs, ophthalmological kit and also use of an ophthalmological composition
CN105348219A (zh) * 2014-08-22 2016-02-24 沈阳药科大学 姜黄素类似物及其制备和应用

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CHENG, WEI-FENG ET AL., FREE RADICAL BIOLOGY AND MEDICINE, vol. 40, 2006, pages 526 - 535
HAN Y M, BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 21, no. 2, 15 January 2011 (2011-01-15)
LEOW, PAY-CHIN ET AL., EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, vol. 71, 2014, pages 67 - 80
WE-MING ET AL., DERRNATOLOGICA SINICA, vol. 29, no. 4, July 2011 (2011-07-01)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12447119B2 (en) 2019-03-18 2025-10-21 Sunstar Americas, Inc. Oral care composition
WO2020212098A1 (fr) 2019-04-15 2020-10-22 Unilever Plc Composition de soins d'hygiène personnelle comprenant de la tétraméthylcurcumine et procédé de production de la composition
CN113710222A (zh) * 2019-04-15 2021-11-26 联合利华知识产权控股有限公司 包含四甲基姜黄素的个人护理组合物及制备该组合物的方法
CN118476975A (zh) * 2024-05-08 2024-08-13 广州环亚化妆品科技股份有限公司 四甲基姜黄素在美白方面的应用

Similar Documents

Publication Publication Date Title
US9499419B2 (en) Methods and compositions for treatment of skin
EP1948236A2 (fr) Procedes et compositions pour le traitement de la peau
US20070041924A1 (en) Sebum Control Compositions Based on Saponins and Sapogenins
US11419801B2 (en) Personal care composition
WO2018077958A1 (fr) Composition de soins personnels comprenant des curcuminoïdes
US12215084B2 (en) 2(1H)-pyridinones and their use to treat inflammatory conditions
KR102012798B1 (ko) 자외선 유도된 지질 과산화를 감소시키는 상승작용 조성물, 제형 및 방법
EP3506874B1 (fr) Composition de soins personnels
EP3532040B1 (fr) Composition de soins personnels
EP3049053B1 (fr) Composition pour la peau et la santé du cuir chevelu
JP2010018546A (ja) コラゲナーゼ阻害剤、皮膚外用剤、口腔用組成物及び食品
JP3503879B2 (ja) 化粧料
EA039502B1 (ru) Композиция для личной гигиены, соединение для такой композиции, способы получения соединения и его применения
EP3785697A1 (fr) Composés cosmétiques avec piperlongumine
BR112021021363B1 (pt) Composto, composição cosmética, processo de preparação de um composto, uso do composto e uso da composição cosmética
WO2019042685A1 (fr) Composition pour soins personnels
JPH10147514A (ja) 化粧料
JP2003277251A (ja) 新規美白化粧品。
JPH11286442A (ja) 炎症因子活性化抑制剤
JPH09241121A (ja) 皮脂分泌抑制剤
US20220125696A1 (en) Inflammation reducing composition containing a cannabis sativa compound
EP3675807A1 (fr) Composition de soins corporels

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17794289

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 17794289

Country of ref document: EP

Kind code of ref document: A1